U.S. markets open in 3 minutes
  • S&P Futures

    4,403.25
    -29.75 (-0.67%)
     
  • Dow Futures

    34,620.00
    -123.00 (-0.35%)
     
  • Nasdaq Futures

    15,001.00
    -193.75 (-1.28%)
     
  • Russell 2000 Futures

    2,269.30
    -7.70 (-0.34%)
     
  • Crude Oil

    76.17
    +0.72 (+0.95%)
     
  • Gold

    1,734.80
    -17.20 (-0.98%)
     
  • Silver

    22.36
    -0.33 (-1.45%)
     
  • EUR/USD

    1.1685
    -0.0016 (-0.14%)
     
  • 10-Yr Bond

    1.5370
    +0.0530 (+3.57%)
     
  • Vix

    20.76
    +3.01 (+16.96%)
     
  • GBP/USD

    1.3553
    -0.0151 (-1.10%)
     
  • USD/JPY

    111.4800
    +0.5020 (+0.45%)
     
  • BTC-USD

    42,181.65
    -1,435.31 (-3.29%)
     
  • CMC Crypto 200

    1,045.50
    -56.02 (-5.09%)
     
  • FTSE 100

    7,064.26
    +0.86 (+0.01%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

CRMD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 20, 2021 in the Class Action Filed on Behalf of CorMedix Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that the Company violated federal securities laws.

Class Period: October 16, 2019 and May 13, 2021
Lead Plaintiff Deadline: September 20, 2021
No obligation or cost to you.

Learn more about your recoverable losses in CRMD:
https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=19597&from=5

CorMedix Inc. NEWS - CRMD NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in CorMedix you have until September 20, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased CorMedix securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the CRMD lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96653